b90e8b6050447e087f0ff0bbf9932093 pmc_27376090.pdf f08836d0ca388d277bec12b3e7e5b4ea8ef7fdfc pmc_27376090.pdf Title: 5263798.dvi Keywords: Creator: LaTeX with hyperref package Producer: Acrobat Distiller 7.0 (Windows); modified using iTextSharp™ 5.4.0 ©2000-2012 1T3XT BVBA (AGPL-version) CreationDate: Wed Jun 8 08:48:11 2016 CEST ModDate: Wed Jun 22 08:14:37 2016 CEST Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 13 Encrypted: no Page size: 600.05 x 800 pts Page rot: 0 File size: 649741 bytes Optimized: no PDF version: 1.3 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- MinionPro-It Type 1C Custom yes no yes 14 0 Minion-Black Type 1C WinAnsi yes no no 15 0 MinionPro-Regular Type 1C Custom yes no yes 16 0 WSLHFE+MinionPro-Regular CID TrueType Identity-H yes yes yes 1 0 MinionMath-Regular Type 1C Custom yes no yes 43 0 MinionMath-Capt Type 1C Custom yes no yes 118 0 Jhove (Rel. 1.6, 2011-01-04) Date: 2019-02-14 18:44:05 CET RepresentationInformation: pmc_27376090.pdf ReportingModule: PDF-hul, Rel. 1.8 (2009-05-22) LastModified: 2018-02-06 08:58:01 CET Size: 649741 Format: PDF Version: 1.3 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 322 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: PageLayout: SinglePage PageMode: UseNone Info: Title: 5263798.dvi Keywords: Creator: LaTeX with hyperref package Producer: Acrobat Distiller 7.0 (Windows); modified using iTextSharp™ 5.4.0 ©2000-2012 1T3XT BVBA (AGPL-version) CreationDate: Wed Jun 08 08:48:11 CEST 2016 ModDate: Wed Jun 22 08:14:37 CEST 2016 ID: 0x4cb19a4d3f0a7ed74c006ddc28d3af3f, 0x05182cab021b97fd1640d7728c0b938f Filters: FilterPipeline: FlateDecode Fonts: Type0: Font: BaseFont: WSLHFE+MinionPro-Regular Encoding: Identity-H ToUnicode: true Type1: Font: BaseFont: MinionPro-Regular FirstChar: 0 LastChar: 255 FontDescriptor: FontName: MinionPro-Regular Flags: Serif, Symbolic FontBBox: -290, -360, 1684, 989 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: MinionMath-Capt FirstChar: 0 LastChar: 255 FontDescriptor: FontName: MinionMath-Capt Flags: Symbolic FontBBox: 23, -12, 396, 451 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: MinionMath-Regular FirstChar: 0 LastChar: 255 FontDescriptor: FontName: MinionMath-Regular Flags: Symbolic FontBBox: 22, -12, 387, 448 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: MinionPro-It FirstChar: 0 LastChar: 255 FontDescriptor: FontName: MinionPro-It Flags: Serif, Symbolic, Italic FontBBox: -201, -360, 1684, 1002 FontFile3: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: Minion-Black FirstChar: 0 LastChar: 243 FontDescriptor: FontName: Minion-Black Flags: Serif, Nonsymbolic, ForceBold FontBBox: -133, -250, 1120, 827 FontFile3: true Encoding: WinAnsiEncoding CIDFontType2: Font: BaseFont: WSLHFE+MinionPro-Regular CIDSystemInfo: Registry: Adobe Registry: Identity Supplement: 0 FontDescriptor: FontName: WSLHFE+MinionPro-Regular Flags: Nonsymbolic FontBBox: -289, -360, 1684, 917 FontFile2: true XMP: application/pdfCirculating Biomarkers of Diabetic Retinopathy: An Overview Based on PhysiopathologySimó-Servat, OlgaSimó, RafaelHernández, CristinaDiabetic retinopathy (DR) is the main cause of working-age adult-onset blindness. The currently available treatments for DR are applicable only at advanced stages of the disease and are associated with significant adverse effects. In early stages of DR the only therapeutic strategy that physicians can offer is a tight control of the risk factors for DR. Therefore, new pharmacological treatments for these early stages of the disease are required. In order to develop therapeutic strategies for early stages of DR new diagnostic tools are urgently needed. In this regard, circulating biomarkers could be useful to detect early disease, to identify those diabetic patients most prone to progressive worsening who ought to be followed up more often and who could obtain the most benefit from these therapies, and to monitor the effectiveness of new drugs for DR before more advanced DR stages have been reached. Research of biomarkers for DR has been mainly based on the pathogenic mechanism involved in the development of DR (i.e., AGEs, oxidative stress, endothelial dysfunction, inflammation, and proangiogenic factors). This review focuses on circulating biomarkers at both early and advanced stages that could be relevant for the prediction or detection of DR.Journal of Diabetes ResearchHindawi Publishing Corporation2016/06/08Research articledoi:10.1155/2016/5263798en Pages: Page: Label: 1 Annotations: Annotation: Subtype: Link Rect: 50, 713, 175, 721 Page: Label: 2 Page: Label: 3 Page: Label: 4 Page: Label: 5 Page: Label: 6 Page: Label: 7 Page: Label: 8 Page: Label: 9 Page: Label: 10 Page: Label: 11 Page: Label: 12 Page: Label: 13 Checksum: 78b53348 Type: CRC32 Checksum: b90e8b6050447e087f0ff0bbf9932093 Type: MD5 Checksum: f08836d0ca388d277bec12b3e7e5b4ea8ef7fdfc Type: SHA-1